Anti-epileptic
Drugs for Pediatrics Market Forecast 2024 to 2032
The treatment of epilepsy
in pediatric patients involves a variety of approaches, including lifestyle
modifications, medical management, and, in some cases, surgical interventions.
When it comes to anti-epileptic drugs (AEDs) for children, several factors are
considered, such as the type of epilepsy, the child's age, overall health, and
any potential side effects. It's important for treatment to be tailored to each
individual child's needs.
The Anti-epileptic Drugs
for Pediatrics Market was valued at USD 695.53 Million in 2022 and is expected
to register a CAGR of 4.61% by 2032.
The prevalence of epilepsy
in children was a significant driver for the market. As awareness and diagnosis
of epilepsy improved, the demand for effective treatments, including AEDs,
increased. This key factor
is expected to drive global market growth during the forecast period.
By Market Vendors:
Mylan N.V
Cephalon, Inc
GlaxoSmithKline plc
Janssen Pharmaceuticals
Novartis AG
Pfizer, Inc
Sanofi S.A
UCB Pharma Limited
Sunovion Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc
Zogenix
GW Pharmaceuticals
Insys
Zynerba
By Types:
1st generation
2nd generation
3rd generation
By Applications:
Hospitals
Retail pharmacies
Online pharmacies
.png)
.png)
No comments:
Post a Comment